Investment

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 23 May 2025. Gyre Therapeutics (NASDAQ: GYRE) priced its public offering of 2.22m shares at US$9.00 each, expecting approximately US$20m in gross proceeds. Underwriters have a 30-day option to buy another 333k shares. Shares closed IMUNON (NASDAQ: IMNN) shares closed up 179% at US$1.16 after it reported that its Phase 2 OVATION 2 study showed significant survival improvements for advanced ovarian cancer patients treated with IMNN-001 plus standar Merus N.V. (NASDAQ: MRUS) reported interim phase 2 data for petosemtamab plus pembrolizumab in head and neck cancer showed a 63% response rate, 79% 12-month OS, and 9-month median PFS in 43 patients, leading Needham to Prothena Corporation (NASDAQ: PRTA) announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based on these resu Immix Biopharma (NASDAQ: IMMX) shares closed down 17% at US$1.99 following NXC-201 data which demonstrated a 71% complete response rate (5/7 patients) in relapsed/refractory AL Amyloidosis in the NEXICART-2 trial and w BriaCell Therapeutics (NASDAQ: BCTX) reported at ASCO 2025 that patients receiving its selected Phase 3 Bria-IMT formulation showed significantly improved PFS (3.6 vs. 2.6 months) and OS (13.4 vs. 6.9 months) compared Biodexa Pharmaceuticals (NASDAQ: BDRX) will hold a 11 June 2025 meeting to propose a share capital reorganization and seek approval to issue new shares for acquisitions and financings, with the latest analyst rating ma

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 14 May 2025. Incannex Healthcare (NASDAQ: IXHL) shares closed up 866% at US$0.82 following the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA). Bluebird Bio (NASDAQ: BLUE), Carlyle, and SK Capital amended their acquisition agreement. Bluebird stockholders can now choose between US$3.00 per share plus a US$6.84 CVR upon achieving a sales milestone, or US$5.00 p Aytu BioPharma (NASDAQ: AYTU) reported quarterly earnings of US$0.21 per share, exceeding analyst estimates losses of US$0.17 by 223.5% and marking a 140.4% improvement from last year’s US$0.52 loss. Quarterly sales re Septerna (NASDAQ: SEPN) and Novo Nordisk (NASDAQ: NVO) have entered an exclusive global collaboration to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardio Plus Therapeutics (NASDAQ: PSTV) is expected to report increased earnings on higher revenue for the quarter ending March 2025. Consensus estimates project a US$0.17 per share loss and US$1.85m in revenue. Surpassing th Quoin Pharmaceuticals (NASDAQ: QNRX) observed clear skin improvement in a pediatric peeling skin syndrome study after 12 weeks. Key endpoints showed significant improvement, and the treatment QRX003 was well-tolerated. Allurion Technologies (NASDAQ: ALUR) shares closed up 26% at US$3 following obesity data. Studies highlighted weight loss and muscle gain with their balloon and AI-powered care, both with and without GLP-1s. Combining

V小姐

4 weeks ago

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 23 April 2025.Ensysce Biosciences (NASDAQ: ENSC) received a USPTO Notice of Allowance for a patent covering composition and method claims for PF9001, a methadone prodrug using its TAAP and MPAR technologies to improve safety in opioid use disorder treatment. Shares closed up 96% at US$3.67.